Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition.

Today’s consumers view quality-tested generics as reliable and effective alternatives to branded medications, says Sujit Paul ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), ...

The generics industry used to lose money on about a third of the drugs it produced, but now it’s more like half, Gaugh said. So when a company stops making a drug, others do not necessarily step ...

Sun Pharmaceutical Industries Ltd. settled claims worth $200 million in an antitrust case in Pennsylvania alleging that the ...

Generics account for nearly 90% of pharmaceutical sales by volume in the U.S. and 80% in Germany. The range is between 85 and 90% in developing countries such as China, India, Russia, Turkey, and ...

Teva Pharmaceutical Industries Ltd. TEVA 2.46% on Monday agreed to buy Allergan PLC’s generics unit for $40.5 billion in cash and stock, in a deal that will vault the Israeli company into the ...

Making the problem worse is that supplies of name-brand Covid-19 drugs are few and far between, and generics of these drugs won’t be available in China due to failed manufacturer negotiations.